Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
The Impact of Positron Emission Tomography with F-18-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
The Journal of urology, v 201(2), pp 322-330
01 Feb 2019
PMID: 30179618
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Purpose: The prospective, multicenter LOCATE (F-18 Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with F-18-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent.
Materials and Methods: Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were suspected to have recurrence based on rising prostate specific antigen levels were enrolled prospectively. Each man had negative or equivocal findings on standard of care imaging. F-18-fluciclovine positron emission tomography/computerized tomography was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient treatment plan before and after scanning, recording changes to the treatment modality (eg salvage radiotherapy to systemic androgen deprivation therapy) as major and changes in a modality (eg modified radiotherapy fields) as other.
Results: Between June 2016 and May 2017, 213 evaluable patients with a median age of 67 years and median prostate specific antigen 1.00 ng/ml were enrolled in study. F-18-fluciclovine avid lesions were detected in 122 of the 213 patients (57%). Overall 126 of the 213 patients (59%) had a change in management after the scan, which were major in 98 of 126 (78%) and in 88 (70%) were informed by positive positron emission tomography/computerized tomography findings. The most frequent major changes were from salvage or noncurative systemic therapy to watchful waiting (32 of 126 cases or 25%), from noncurative systemic therapy to salvage therapy (30 of 126 or 24%) and from salvage therapy to noncurative systemic therapy (11 of 126 or 9%).
Conclusions: F-18-fluciclovine positron emission tomography/computerized tomography detected 1 or more recurrence sites in the majority of men with biochemical recurrence, frequently resulting in major changes to management plans. Future studies will be planned to determine whether a management change leads to improved outcomes.
Metrics
Details
- Title
- The Impact of Positron Emission Tomography with F-18-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
- Creators
- Gerald L. Andriole - Washington University in St. LouisLale Kostakoglu - Icahn School of Medicine at Mount SinaiAlbert Chau - Blue Earth DiagnosticsFenghai Duan - Brown UniversityUmar Mahmood - Massachusetts General HospitalDavid A. Mankoff - University of PennsylvaniaDavid M. Schuster - Emory UniversityBarry A. Siegel - MallinckrodtLee P. AdlerLaurence H. BelkoffDaniel BurzonPaul DatoMichael FarwellStephen FogelsonPeter GardinerLucy HannaJohn M. HoffmanCharles IntenzoDavid JosephsonJed KaminetskyMichael KipperBorys KrynyckyiKaren E. LinderHelga MarquesJohn MelnickMatthew P. MillerWilliam OhShaile PhilipsJudith RoseBital Savir-BaruchDaniel J. StevensAshutosh TewariPrzemyslaw TwardowskiPenelope WardMartha WassermanSharon WeickJian Q. (Michael) YuLOCATE Study Grp
- Publication Details
- The Journal of urology, v 201(2), pp 322-330
- Publisher
- Elsevier
- Number of pages
- 9
- Grant note
- St. Louis Men's Group Against Cancer NCI (National Cancer Institute); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) NIDDK (National Institutes of Diabetes and Digestive and Kidney Diseases) Peter Michael Foundation Barnes-Jewish Hospital Foundation U10CA180794 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) PCF (Prostate Cancer Foundation)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:000455997500087
- Scopus ID
- 2-s2.0-85053441020
- Other Identifier
- 991021916798504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Urology & Nephrology